Josh Baltzell

Josh has spent over 25 years in the healthcare industry working across a broad range of responsibilities and companies ranging from early stage product development and innovation all the way up to public offerings and mergers and acquisitions for mature companies.

Josh currently serves as a Venture Partner at SightLine partners where he focuses on sourcing and managing investments in the health care industry.  Prior to SightLine, Josh was a Managing Director at Split Rock Partners. A lead investor and board member in companies with an aggregate, realized value of over $2 billion, some of his notable past successes as a venture investor include Ardian – acquired by Medtronic for ~$800M, Entellus Medical – acquired by Stryker for ~$700M, RF Surgical – acquired by Medtronic for $235M and SkinMedica – acquired by Allergan for $350M.

In addition to Aegea, Josh currently serves as a board director at  Colorescience, Koya Medical,  Magnolia Medical, and ViewPoint Medical and also serves as an advisor to TMRW.

Josh earned Bachelor degrees in Economics and Philosophy from St. Olaf College and an M.B.A. from The Carlson School at the University of Minnesota.


Important Safety Information:

The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.